Intubation, IntratrachealPhase 4NCT04872881
Comparison of Effectiveness of Different Airway Management Methods During Percutaneous Tracheostomy
A Phase 4 study testing Endotracheal Tube Insertion, Laryngeal Mask Insertion and Fiberoptic Bronchoscopy in people with Intubation, Intratracheal and Tracheostomy, run by Bozyaka Training and Research Hospital.
Trial summary
Tracheostomy is a vital procedure in the ICU to maintain the airway and prevent complications that may occur due to intubation. It helps reduce the dead space volume, airway resistance and provides comfort to the patients during the weaning from mechanical ventilation. Read more about this study
- Who is it for?
- Ages 18 to 95 years
- Conditions the study is for
- Intubation, Intratracheal, Tracheostomy, Laryngeal Masks
- What is being tested?
- Endotracheal Tube Insertion, Laryngeal Mask Insertion and Fiberoptic Bronchoscopy
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2021to 1 Oct 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 95 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Non-pregnant patients over 18 years of age
- Patients who need a tracheostomy
- Patients whose opening method of tracheostomy is suitable for percutaneous tracheostomy.
Who cannot join
- Refusal of the procedure by the patient or her legal representative
- Patients under the age of 18
- Body mass index> 35 patient group
- Patients with a mass in the neck region for any reason
- Skin infection at the procedure site
- Coagulopathy
- Inability to palpate the cricoid cartilage
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Comparison of Effectiveness of Different Airway Management Methods During Fiberoptic Bronchoscopy Assisted Percutaneous Tracheostomy
Tracheostomy is a vital procedure in the ICU to maintain the airway and prevent complications that may occur due to intubation. It helps reduce the dead space volume, airway resistance and provides comfort to the patients during the weaning from mechanical ventilation. Two methods are widely used in Percutaneous Dilatational Tracheostomy (PDT): The multiple dilation method (Ciaglia) and the Griggs method.Griggs method will be used in the study.
The Griggs Method: A 10-15 millimeter skin incision is made between the level of the second-third tracheal rings. The location of the needle is confirmed by entering the trachea with an injector filled with 2-3 mL saline from the midline and aspirating air. A J-tipped guidewire is advanced through the needle and the needle is removed. A special forceps with a channel at the tip, through which the guidewire can pass is used in this method. The forceps advanced through the guidewire and then subcutaneous tissues and trachea are dilated in one or two steps. When the stoma is large enough to insert the cannula, it is placed in the trachea and fixed.
Read more
Patients who will undergo tracheostomy in the ICU will be included in the study and randomly assigned into two groups. Two different methods, endotracheal tube (ET) or laryngeal mask (LMA), will be used during the tracheostomy for airway management. In both methods, fiberoptic bronchoscopy will assist the procedure.
Researchers aim to compare the two airway management methods in terms of complications, procedure time, and the number of staff needed.
Read the detailed description
Protection of the airway during percutaneous tracheostomy can be achieved with an endotracheal tube (ETT) or laryngeal mask (LMA).Researchers aimed to compare the use of ETT and LMA in this prospective, randomized study.
Multiple blood gas analyses will be performed during the procedure. Airway failure rates, total procedure time, the occurrence of gastric distension and regurgitation, number of staff needed, complications (Hypercarbia, hypoxia, etc.), and hemodynamic parameters (Non-invasive blood pressure, pulse oximeter, electrocardiogram) will be compared.
Patients will be divided into two groups with simple randomization. A-priori study with 14 patients suggested 52 patients are needed for statistical significance (G*Power 3.1 software was used). Patients will be reviewed for suitability for procedure as stated in the inclusion criteria. Patients and/or relatives will be informed about the study and informed consent will be obtained. Invasive arterial blood pressure monitoring of the patients will be available. Before the procedure, the patients' fasting period for 6 hours will be completed and the nasogastric catheter will be removed. Arterial blood gas sample will be checked before the procedure begins. By placing a transverse elevation under the shoulders, the patients' neck will be extended as appropriate. Patients will be positioned after induction with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl IV, and positioning time will be recorded. Propofol infusion at the dose of 6 mg/kg/hour will be started. Electrocautery will be available. Patients will be mechanically ventilated with a controlled mode (CMV) with 7ml/kg tidal volume, 15/min frequency, and 5 cmH2O PEEP. Preoxygenation will be made with 100% FiO2 for 5 minutes.
ETT Group: ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).
LMA Group: After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).
After the ventilation is provided, arterial blood gas samples will be analyzed at the 3rd, 6th, and 10th minutes and every 5 minutes afterward until the end of the procedure. In both groups, fiberoptic bronchoscopy will assist the procedure and "Duration of the Confirmation of the Incision Site" will be noted. The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site. The area will be cleaned with iodide skin antiseptic, covered with a sterile cover, and surgical tools and tracheostomy kit will be prepared for the procedure. This will be recorded as "Preparation Time". Tracheostomy will preferably be performed between the 2nd and 3rd cartilage rings but one upper or lower level will be used if needed (per patients' anatomy). Local anesthesia will be applied for the incision site with 4 ml of local anesthetic solution containing %2 lidocaine and %0,00125 epinephrine. "Procedure Time" will start with skin incision and end with successful ventilation after the tracheostomy cannula cuff is inflated.
Gastric distension, hypoxia, regurgitation, hemodynamic parameters (every 3 minutes), complications, and the number of staff will be recorded. When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with an anteroposterior chest x-ray.
SPSS (Statistical Package for Social Sciences version 24) was used for statistical calculation. Parametric test results were reported as mean and standard deviation and non-parametric test results as number and percentage or median and interquartile range. The compliance of the data to normal distribution was determined by the single sample Kolmogorov-Smirnov test. Normally distributed quantitative data were compared with the independent sample T-Test, quantitative data that did not follow normal distribution were compared with the Mann-Whitney U test. A Chi-square test was used to compare qualitative data.
The significance level was determined as p <0.05 at the 95% confidence interval for the analyzes.
- Being tested
- Endotracheal Tube Insertion, Laryngeal Mask Insertion, Fiberoptic Bronchoscopy, Radial Artery Monitoring, Anteroposterior chest x-ray
- Keywords
- Percutan Dilatational Tracheostomy, Intensive Care Units
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endotracheal Tube InsertionProcedure or surgery
ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
Laryngeal Mask InsertionProcedure or surgery
After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
Fiberoptic BronchoscopyProcedure or surgery
After the patients' airway is established, the trachea and the process area will be displayed by the physician.
The success rate will be increased by performing the procedure with fiberoptic bronchoscopy.
Radial Artery MonitoringProcedure or surgery
The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
Anteroposterior chest x-rayDiagnostic test
When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
Arterial Blood Gas AnalysesDiagnostic test
Hypoxia, acidosis and carbon dioxide increase will be followed
Propofol FreseniusDrug
2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
RocuroniumDrug
Also called Muscuron
0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
FentanylDrug
1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
| Study group | Role | What they receive |
|---|---|---|
| ETT Group | Active comparator | ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords) Receives: Procedure: Endotracheal Tube Insertion; Procedure: Fiberoptic Bronchoscopy; Procedure: Radial Artery Monitoring; Diagnostic Test: Anteroposterior chest x-ray; Diagnostic Test: Arterial Blood Gas Analyses; Drug: Propofol Fresenius; Drug: Rocuronium; Drug: Fentanyl |
| LMA Group | Active comparator | After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords) Receives: Procedure: Laryngeal Mask Insertion; Procedure: Fiberoptic Bronchoscopy; Procedure: Radial Artery Monitoring; Diagnostic Test: Anteroposterior chest x-ray; Diagnostic Test: Arterial Blood Gas Analyses; Drug: Propofol Fresenius; Drug: Rocuronium; Drug: Fentanyl |
What is being measured
The primary outcome is the main question the study is designed to answer.
Arterial Blood Gas Analysis
Monitoring of hypoxia, acidosis, and carbon dioxide
Measured: Before the procedure
Arterial Blood Gas Analysis
Monitoring of hypoxia, acidosis, and carbon dioxide
Measured: 3rd minute after ventilation
Arterial Blood Gas Analysis
Monitoring of hypoxia, acidosis, and carbon dioxide
Measured: 6th minute after ventilation
Arterial Blood Gas Analysis
Monitoring of hypoxia, acidosis, and carbon dioxide
Measured: 10th minute after ventilation
Arterial Blood Gas Analysis
Monitoring of hypoxia, acidosis, and carbon dioxide
Measured: When the tracheostomy cannula cuff is inflated
Positioning time
By placing a transverse elevation under the shoulders, the patients' neck will be extended as approprite.
Measured: Before the procedure
The Reposition Time
The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway".
Measured: Before the procedure
The LMA Insertion Time
The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway"
Measured: Before the procedure
Duration of the Confirmation of the Incision Site
The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site
Measured: Before the procedure
Preparation Time
Area will be cleaned with iodide skin antiseptic, covered with a sterile cover and surgical tools and tracheostomy kit will be prepared for the procedure
Measured: Before the procedure
Procedure Time
"Procedure Time" will start with skin incision and end with successful ventilation after tracheostomy cannula cuff is inflated.
Measured: 15 minutes after the procedure begins
Secondary outcomes (7)
Incidence of gastric distension
Measured: Throughout the tracheostomy procedure
Incidence of hypoxia
Measured: Throughout the tracheostomy procedure
Incidence of regurgitation
Measured: Throughout the tracheostomy procedure
The number of staff needed
Measured: Throughout the tracheostomy procedure
Heart rate
Measured: Every 3 minutes during the procedure
Blood pressure
Measured: Every 3 minutes during the procedure
Pulse oximeter
Measured: Every 3 minutes during the procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2021
- Study start1 May 2021 (estimated)
- Primary completion1 Aug 2021 (estimated)
- Study completion1 Oct 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intubation, IntratrachealStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- There are two groups: ETT Group and LMA Group
- Masking
- None (open label)
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bozyaka Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elif Göktaş, Bozyaka Training and Research Hospital
- Investigators
- Elif Göktaş, Study chair, Izmir Bozyaka Research and Trainings HospitalZeki T TEKGUL, Study chair, Izmir Bozyaka Research and Trainings HospitalHüseyin ÖZKARAKAŞ, Study chair, Izmir Bozyaka Research and Trainings Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04872881
- Sponsor's protocol ID
- eliftez
- Status last verified
- Apr 2021
- First submitted
- 22 Apr 2021
- Last updated
- 5 May 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Effectiveness of Different Airway Management Methods During Fiberoptic Bronchoscopy Assisted Percutaneous Tracheostomy
- ClinicalTrials.gov ID
- NCT04872881
- Acronym / sponsor ID
- eliftez
- Keywords
- Percutan Dilatational Tracheostomy, Intensive Care Units
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Bozyaka Training and Research HospitalUniversity, hospital or other
- Study start
- 1 May 2021 (estimated)
- Primary completion
- 1 Aug 2021 (estimated)
- Study completion
- 1 Oct 2021 (estimated)
- First posted
- 5 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tracheostomy is a vital procedure in the ICU to maintain the airway and prevent complications that may occur due to intubation. It helps reduce the dead space volume, airway resistance and provides comfort to the patients during the weaning from mechanical ventilation. Two methods are widely used in Percutaneous Dilatational Tracheostomy (PDT): The multiple dilation method (Ciaglia) and the Griggs method.Griggs method will be used in the study.
The Griggs Method: A 10-15 millimeter skin incision is made between the level of the second-third tracheal rings. The location of the needle is confirmed by entering the trachea with an injector filled with 2-3 mL saline from the midline and aspirating air. A J-tipped guidewire is advanced through the needle and the needle is removed. A special forceps with a channel at the tip, through which the guidewire can pass is used in this method. The forceps advanced through the guidewire and then subcutaneous tissues and trachea are dilated in one or two steps. When the stoma is large enough to insert the cannula, it is placed in the trachea and fixed.
Patients who will undergo tracheostomy in the ICU will be included in the study and randomly assigned into two groups. Two different methods, endotracheal tube (ET) or laryngeal mask (LMA), will be used during the tracheostomy for airway management. In both methods, fiberoptic bronchoscopy will assist the procedure.
Researchers aim to compare the two airway management methods in terms of complications, procedure time, and the number of staff needed.
Detailed description
Protection of the airway during percutaneous tracheostomy can be achieved with an endotracheal tube (ETT) or laryngeal mask (LMA).Researchers aimed to compare the use of ETT and LMA in this prospective, randomized study.
Multiple blood gas analyses will be performed during the procedure. Airway failure rates, total procedure time, the occurrence of gastric distension and regurgitation, number of staff needed, complications (Hypercarbia, hypoxia, etc.), and hemodynamic parameters (Non-invasive blood pressure, pulse oximeter, electrocardiogram) will be compared.
Patients will be divided into two groups with simple randomization. A-priori study with 14 patients suggested 52 patients are needed for statistical significance (G*Power 3.1 software was used). Patients will be reviewed for suitability for procedure as stated in the inclusion criteria. Patients and/or relatives will be informed about the study and informed consent will be obtained. Invasive arterial blood pressure monitoring of the patients will be available. Before the procedure, the patients' fasting period for 6 hours will be completed and the nasogastric catheter will be removed. Arterial blood gas sample will be checked before the procedure begins. By placing a transverse elevation under the shoulders, the patients' neck will be extended as appropriate. Patients will be positioned after induction with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl IV, and positioning time will be recorded. Propofol infusion at the dose of 6 mg/kg/hour will be started. Electrocautery will be available. Patients will be mechanically ventilated with a controlled mode (CMV) with 7ml/kg tidal volume, 15/min frequency, and 5 cmH2O PEEP. Preoxygenation will be made with 100% FiO2 for 5 minutes.
ETT Group: ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).
LMA Group: After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).
After the ventilation is provided, arterial blood gas samples will be analyzed at the 3rd, 6th, and 10th minutes and every 5 minutes afterward until the end of the procedure. In both groups, fiberoptic bronchoscopy will assist the procedure and "Duration of the Confirmation of the Incision Site" will be noted. The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site. The area will be cleaned with iodide skin antiseptic, covered with a sterile cover, and surgical tools and tracheostomy kit will be prepared for the procedure. This will be recorded as "Preparation Time". Tracheostomy will preferably be performed between the 2nd and 3rd cartilage rings but one upper or lower level will be used if needed (per patients' anatomy). Local anesthesia will be applied for the incision site with 4 ml of local anesthetic solution containing %2 lidocaine and %0,00125 epinephrine. "Procedure Time" will start with skin incision and end with successful ventilation after the tracheostomy cannula cuff is inflated.
Gastric distension, hypoxia, regurgitation, hemodynamic parameters (every 3 minutes), complications, and the number of staff will be recorded. When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with an anteroposterior chest x-ray.
SPSS (Statistical Package for Social Sciences version 24) was used for statistical calculation. Parametric test results were reported as mean and standard deviation and non-parametric test results as number and percentage or median and interquartile range. The compliance of the data to normal distribution was determined by the single sample Kolmogorov-Smirnov test. Normally distributed quantitative data were compared with the independent sample T-Test, quantitative data that did not follow normal distribution were compared with the Mann-Whitney U test. A Chi-square test was used to compare qualitative data.
The significance level was determined as p <0.05 at the 95% confidence interval for the analyzes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- There are two groups: ETT Group and LMA Group
| Arm | Type | Receives |
|---|---|---|
| ETT Group | Active comparator | Procedure: Endotracheal Tube Insertion, Procedure: Fiberoptic Bronchoscopy, Procedure: Radial Artery Monitoring, Diagnostic Test: Anteroposterior chest x-ray, Diagnostic Test: Arterial Blood Gas Analyses, Drug: Propofol Fresenius, Drug: Rocuronium, Drug: FentanylETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords) |
| LMA Group | Active comparator | Procedure: Laryngeal Mask Insertion, Procedure: Fiberoptic Bronchoscopy, Procedure: Radial Artery Monitoring, Diagnostic Test: Anteroposterior chest x-ray, Diagnostic Test: Arterial Blood Gas Analyses, Drug: Propofol Fresenius, Drug: Rocuronium, Drug: FentanylAfter selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords) |
Who may qualify
- Ages
- 18 to 95 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Non-pregnant patients over 18 years of age
- Patients who need a tracheostomy
- Patients whose opening method of tracheostomy is suitable for percutaneous tracheostomy.
Key exclusion criteria (7 listed)
- Refusal of the procedure by the patient or her legal representative
- Patients under the age of 18
- Body mass index> 35 patient group
- Patients with a mass in the neck region for any reason
- Skin infection at the procedure site
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endotracheal Tube InsertionETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords) | Procedure or surgery | ETT Group |
| Laryngeal Mask InsertionAfter selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. | Procedure or surgery | LMA Group |
| Fiberoptic BronchoscopyAfter the patients' airway is established, the trachea and the process area will be displayed by the physician. The success rate will be increased by performing the procedure with fiberoptic bronchoscopy. | Procedure or surgery | ETT Group, LMA Group |
| Radial Artery MonitoringThe radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way. | Procedure or surgery | ETT Group, LMA Group |
| Anteroposterior chest x-rayWhen the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray. | Diagnostic test | ETT Group, LMA Group |
| Arterial Blood Gas AnalysesHypoxia, acidosis and carbon dioxide increase will be followed | Diagnostic test | ETT Group, LMA Group |
| Propofol Fresenius2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started. | Drug | ETT Group, LMA Group |
| RocuroniumAlso: Muscuron0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given. | Drug | ETT Group, LMA Group |
| Fentanyl1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given. | Drug | ETT Group, LMA Group |
Primary outcome
Arterial Blood Gas Analysis
Time frame: Before the procedure
Monitoring of hypoxia, acidosis, and carbon dioxide
Arterial Blood Gas Analysis
Time frame: 3rd minute after ventilation
Monitoring of hypoxia, acidosis, and carbon dioxide
Arterial Blood Gas Analysis
Time frame: 6th minute after ventilation
Monitoring of hypoxia, acidosis, and carbon dioxide
Arterial Blood Gas Analysis
Time frame: 10th minute after ventilation
Monitoring of hypoxia, acidosis, and carbon dioxide
Arterial Blood Gas Analysis
Time frame: When the tracheostomy cannula cuff is inflated
Monitoring of hypoxia, acidosis, and carbon dioxide
Positioning time
Time frame: Before the procedure
By placing a transverse elevation under the shoulders, the patients' neck will be extended as approprite.
The Reposition Time
Time frame: Before the procedure
The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway".
The LMA Insertion Time
Time frame: Before the procedure
The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway"
Duration of the Confirmation of the Incision Site
Time frame: Before the procedure
The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site
Preparation Time
Time frame: Before the procedure
Area will be cleaned with iodide skin antiseptic, covered with a sterile cover and surgical tools and tracheostomy kit will be prepared for the procedure
Procedure Time
Time frame: 15 minutes after the procedure begins
"Procedure Time" will start with skin incision and end with successful ventilation after tracheostomy cannula cuff is inflated.
7 secondary outcomes
Incidence of gastric distension
Time frame: Throughout the tracheostomy procedure
Incidence of hypoxia
Time frame: Throughout the tracheostomy procedure
Incidence of regurgitation
Time frame: Throughout the tracheostomy procedure
The number of staff needed
Time frame: Throughout the tracheostomy procedure
Heart rate
Time frame: Every 3 minutes during the procedure
Blood pressure
Time frame: Every 3 minutes during the procedure
Pulse oximeter
Time frame: Every 3 minutes during the procedure
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2021.
- Laryngeal mask airway vs endotracheal tube to facilitate bedside percutaneous tracheostomy in critically ill patients: a prospective comparative study.Link provided by the sponsor.
Related trials for Intubation, Intratracheal
Not yet recruitingObservational study
AI-assisted Tracheal Intubation in Children
Intubation
Not yet recruiting
AI Smart Glasses Feedback for Intubation Training in Medical Students
Intubation, Intratracheal, Medical Education
Recruiting
Development and Preliminary Validation of Intelligent Video Laryngoscope for Emergency Use
Critically Ill Patients Requiring Mechanical Ventilation
Recruiting
Effect of a Brief Educational Intervention on Endotracheal Tube Cuff Pressure
Intubation, Endotracheal Tube Cuff Pressure
Recruiting
Hyperangulated vs Standard Videolaryngoscopy vs Direct Laryngoscopy for Double-Lumen Endobronchial Tube Intubation
Endobronchial Intubation, Double Lumen Tube Intubation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elif Göktaş study chair
Izmir Bozyaka Research and Trainings Hospital
Zeki T TEKGUL study chair
Izmir Bozyaka Research and Trainings Hospital
Hüseyin ÖZKARAKAŞ study chair
Izmir Bozyaka Research and Trainings Hospital
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Endotracheal Tube Insertion, Laryngeal Mask Insertion and Fiberoptic Bronchoscopy in people with Intubation, Intratracheal and Tracheostomy, run by Bozyaka Training and Research Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Elif Göktaş (05062073485, e.goktas44@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Arterial Blood Gas Analysis (time frame: Before the procedure). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.